All Articles

Three-year ATTRACTION-2 follow-up results confirm the long-term efficacy of nivolumab in patients with previously treated advanced gastric/gastroesophageal junction (GEJ) cancer.

KEYNOTE-181 results show improved overall survival in patients with advanced esophageal cancer treated with second-line pembrolizumab compared with chemotherapy.

Recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma were released by an expert panel.

Differences in survival time by tumor response were found during evaluation of nivolumab therapy in advanced gastric cancer.

The use of PET to direct therapy after nonresponse to induction chemotherapy improved overall survival in patients with resectable esophageal cancer.

Promising response rates were reported in a clinical trial of neoadjuvant sintilimab with CapeOx in patients with resectable, locally advanced gastric/gastroesophageal junction (GEJ) cancer.

MAHOGANY Cohort A clinical trial results reveal margetuximab and retifanlimab combination treatment led to tumor response with an acceptable safety profile.

An early-phase clinical trial of nivolumab with radiotherapy in patients with relapsed unresectable/recurrent gastric cancer demonstrated prolonged patient survival.

Statistically meaningful improvement in progression-free survival, overall survival, and objective response rate was found in patients with advanced gastric cancer treated with bemarituzumab and modified FOLFOX6.

Overall survival and progression-free survival were improved with first-line treatment of camrelizumab with chemotherapy in patients with advanced or metastatic esophageal squamous-cell carcinoma (ESCC).